原发性硬化性胆管炎药物治疗进展
Advances in drug therapy for primary sclerosing cholangitis
盛夏 1纪庆明 2李昕宇 2王丽宏 3牛俊奇4
作者信息
- 1. 吉林大学第一医院 干部病房,长春 130021
- 2. 吉林大学第一医院 重症医学科,长春 130021
- 3. 哈尔滨医科大学附属第二医院内分泌与代谢病科,哈尔滨 150000
- 4. 吉林大学第一医院 感染病中心肝病科,长春 130021
- 折叠
摘要
原发性硬化性胆管炎(PSC)是一种以慢性进行性胆管炎症为特征的胆汁淤积性疾病,在我国发病率低,预后差,尚无药物治疗能改变PSC的进程,肝移植是唯一有效治疗手段,移植后5年生存率可达85%.基于PSC现状,药物治疗面临巨大挑战.目前治疗PSC的药物尚处于临床试验阶段,初步显示出应用前景,其中熊去氧胆酸是研究最广泛、最常用的药物.除此之外,还有很多新兴药物正在研究中.本文将围绕PSC最新药物治疗进展进行概述.
Abstract
Primary sclerosing cholangitis(PSC)is a cholestatic disease characterized by chronic progressive bile duct inflammation and has a low incidence rate and poor prognosis in China.There is still no drug therapy that can change the course of PSC,and liver transplantation is the only effective treatment for PSC,with a 5-year survival rate of 85%after transplantation.Drug therapy for PSC is facing great challenges based on the current status of PSC.At present,drugs for the treatment of PSC are in the stage of clinical trials and have shown certain application prospect,among which ursodeoxycholic acid is the most widely studied and commonly used drug.In addition,there are many emerging drugs in the pipeline.This article summarizes the latest advances in drug therapy for PSC.
关键词
胆管炎,硬化性/熊去氧胆酸/奥贝胆酸/药物疗法Key words
Cholangitis,Sclerosing/Ursodeoxycholic Acid/Obecholic Acid/Drug Therapy引用本文复制引用
出版年
2024
国家科技期刊平台
NSTL
万方数据